Mitsubishi Tanabe Pharma Presents RADICAVA ORS® For Treatment Of ALS At 2024 NASP Annual Meeting

Today, Mitsubishi Tanabe Pharma America, Inc. (MTPA) announced two presentations that are to be held at the 2024 National Association of Specialty Pharmacy (NASP) Annual Meeting and Expo in Nashville, TN, from 6th to 9th October. These presentations will focus on patient demographics, treatment duration, progression milestones, and healthcare resource utilization for individuals living with amyotrophic lateral sclerosis (ALS) treated with RADICAVA ORS® (edaravone).

Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at MTPA, said in a statement, "MTPA is pleased to share these important findings on RADICAVA ORS at the 2024 NASP Annual Meeting. These results underscore our commitment to advancing medical knowledge and improving patient care, offering a comprehensive view of how our innovations impact clinical outcomes and healthcare resource utilisation."

These presentations will include the real-world analysis of patient-focused demographics, the duration of treatment, and the progressive milestones of the first RADICAVA ORS dosing. The presentations will consist of data from Optum’s Clinformatics® Data Mart (CDM) and focus on the clinical characteristics and healthcare resource usage of RADICAVA ORS in treating ALS patients.

Presentations by Malgorzata Ciepielewska, will include topics like — “A Preliminary Analysis of Oral Edaravone – Treated Patients With Amyotrophic Lateral Sclerosis Enrolled in a US-Based Administrative Claims Database” and “Healthcare Resource Utilization of Oral Edaravone – Treated Patients With Amyotrophic Lateral Sclerosis Enrolled in a US-Based Administrative Claims Database” on the 7th and 8th of October.